Researchers grew and transformed embryonic stem cells into cartilage cells also known as chondrocytes.
"This work represents an important step forward in treating cartilage damage by using embryonic stem cells to form new tissue, although it's still in its early experimental stages," said Professor Sue Kimber and her team in the Faculty of Life Sciences at The University of Manchester.
During the study, the team analysed the ability of embryonic stems cells to become precursor cartilage cells. They were then implanted into cartilage defects in the knee joints of rats.
Further study of this newly regenerated cartilage showed that cartilage cells from embryonic stem cells were still present and active within the tissue.
Developing and testing this protocol in rats is the first step in generating the information needed to run a study in people with arthritis.
Before this will be possible more data will need to be collected to check that this protocol is effective and that there are no toxic side-effects, researchers said.
They say that this study is very promising as not only did this protocol generate new, healthy-looking cartilage but also importantly there were no signs of any side-effects such as growing abnormal or disorganised, joint tissue or tumours.
Chondrocytes created from adult stem cells are currently being experimentally used but as they cannot be currently be produced in large amounts the procedure is expensive.
With their huge capacity to proliferate, embryonic stem cells, which can be manipulated to form almost any type of mature cell, offer the possibility of high-volume production of cartilage cells.
Their use would also be cheaper and applicable to greater number of arthritis patients, the researchers claim.
"We've shown that the protocol we've developed has strong potential for developing large numbers of chondrogenic cells appropriate for clinical use," Kimber added.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
